BI 187004 CL

Drug Profile

BI 187004 CL

Alternative Names: BI-187004; BI-187004-CL; VTP-34072

Latest Information Update: 11 Apr 2017

Price : $50

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Boehringer Ingelheim Pharmaceuticals
  • Class
  • Mechanism of Action 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 Dec 2015 Boehringer Ingelheim and Vitae Pharmaceuticals terminate their license for BI 187004 CL
  • 21 Dec 2015 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in Germany (PO)
  • 21 Dec 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top